Celyad Oncology is at the forefront of cutting-edge immunotherapy and is hopeful of providing a new way forward for patients with relapsed/refractory multiple myeloma. After receiving FDA approval on July 14th to begin Phase I trials, they plan to be in the clinic with their first patient the end of 2020.
The Belgian clinical-stage biotechnology company is focused on the discovery and development of chimeric antigen receptor T cell (CAR-T) therapies for cancer. Celyad Oncology is also developing CYAD-101, an investigational non-gene edited, allogeneic NKG2D-based CAR-T therapy for metastatic colorectal cancer.
The two primary types of cell therapy are autologous and allogeneic. Autologous CAR-T therapy uses the transplantation and genetic editing of a patients own immune cells in a single batch, while an allogeneic transplant uses immune cells from a donor manufactured in large batches. Celyad Oncology is only the fourth company to proceed to Phase I with an allogeneic CAR-T working against a target known as B-cell maturationantigen (BCMA), which is highly expressed in multiple myeloma patients.
The Phase I objectives for CYAD-211 are to establish the viability, effectiveness and further possibilities opened up by the shRNA-based technology. Along with analyzing the merits of targeting BCMA with a CAR-T, Celyad Oncology Chief Executive Officer Filippo Petti shared that the companys first priority is to prove the premise that ShRNA bears out for allogeneic CAR-T.
The first level is to get into the clinic and evaluate the question, is shRNA a novel, non-gene edited allogeneic approach to CAR-T? Where the majority of our peers in the space work on genome using the gene editing technology, if we can show that another non-gene editing technology like ShRNA works, it would just open up the whole field in terms of allogeneic CAR-T. It would demonstrate that we have an unencumbered asset and technology platform for us to create next-generation CAR-T candidates with, Petti said. Well know very quickly, within the first few patients, if we are seeing an absence of graft-versus-host disease, and if ShRNA carries its weight in terms of being an allogeneic technology.
He expects to have a sense of how competitive the data is in terms of both safety and clinical efficacy by end of year 2021.
Dr. Laurence Cooper, Chief Executive Officer (CEO) of Ziopharm Oncology, who is also a veteran innovator in pairing genetic engineering with immunotherapies, explained that Graft-versus-Host Disease (GvHD) is one of biggest challenges facing companies who take the allogeneic approach.
When you put in third party cells, those cells get really confused right off the bat because now theyre somewhere new, and all of a sudden they perceive the patient as the threat. This can result in Graft-versus-Host Disease, an autoimmune disease triggered by the native biology in the T cell through its T cell receptor, Cooper said. The engineering that youre talking about is to eliminate that threat. Some cut out the genetic material coding for the endogenous T cell receptor so that now a T cell can go into another person, and it cant perceive the threat anymore because its lost its antennae. Another way is to prevent expression of the T cell receptor. Now the T cell can do something useful if you put in a CAR, it can go off and targetBCMA.
Frdric F. Lehmann, Head of the Oncology Franchise at Celyad Oncology, explained how the shRNA-based therapy is engineered to reign in the cells new rampant disregard for threat, and lessen the chances of an autoimmune response.
One of the innovations for CYAD-211 is incorporating in the vector a short hairpin RNA (shRNA) targeting the CD3 subunit of the T cell Receptor (TCR). This effectively downregulates the surface expression of the TCR thereby inhibiting the signaling that would lead to Graft-versus-Host Disease, Lehmann said.
A notable drawback with the autologous approach to CAR-T therapy is that it is costly and time-consuming. Petti explained how CYAD-211 not only has the potential to improve efficacy, but also make the treatment process more scalable and therefore economically expedient.
When it comes to commercialization, because we use an all-in-one-vector approach, we benefit from less manipulations during manufacturing, allowing us to enrich for the engineered cells we want, which eventually could help during potential commercialization of a product thats streamlined, Petti said.
He added that the all-in-one vector approach increases efficiency because, as opposed to the case with the gene editing process, they are able to accomplish everything in a single step.
Long term, Cooper is excited about the possibility that, whether autologous or allogeneic, immunotherapy may one day replace bone marrow transplants, or even chemotherapy, but emphasized that it must be made accessible.
If these immunotherapies can be advanced really to replace chemotherapy, not to replace transplantation for liquid tumors, but to replace chemotherapy, which is a huge goal if you can get it to do that, you have to bring the costs down to make it available for the masses, inside first world economies as well as less privileged societies, Cooper said.
In 2013, the overall five-year survival rate for multiple myeloma stood at 49.6%. Relapsed/refractory patients for whom currently available treatments have failed, are the intended beneficiaries of much of the biotechnology work being done in this area. And impressive steps have recently been made.
GlaxoSmithKlines BLENREP (BelantamabMafodotin) is the first in its class to work against BCMA, while Janssen Biotechs (Johnson & Johnson) DARZALEX (Daratumumab) is the first human Anti-CD38 monoclonal antibody in the space. After their 2019 acquisition of Celgene Corp., Bristol-Myers Squibb gained Revlimid (Lenalidomide), a hematology drug approved for multiple myeloma, and Amgen and Takeda have popular proteasome inhibitors on the market.
With Celyad Oncology moving the needle forward once again, the future looks a little brighter for multiple myeloma patients.
Continue reading here:
Celyad's High Hopes for a Path Forward in Cancer Immunotherapy with CYAD-211 - BioSpace
- Conservative News Websites Hacked, Replaced With Page Leaking Private Information - Mediaite - May 3rd, 2024 [May 3rd, 2024]
- Bring Me The Horizon's album 'POST HUMAN: NeX GEn' will arrive this summer - NME - January 10th, 2024 [January 10th, 2024]
- Bring Me The Horizon - Post Human: Next Gen - East Oregonian - January 10th, 2024 [January 10th, 2024]
- From Usher to Green Day, these are the top albums you'll want to hear in 2024! - Yahoo News UK - January 10th, 2024 [January 10th, 2024]
- Bring Me The Horizon Unveils New Single 'Kool-Aid', Teases Upcoming Album 'Post Human' - BNN Breaking - January 10th, 2024 [January 10th, 2024]
- SPRR1A is a key downstream effector of MiR-150 during both ... - Nature.com - July 19th, 2023 [July 19th, 2023]
- Daily briefing: Birds build nests from anti-bird spikes - Nature.com - July 19th, 2023 [July 19th, 2023]
- Windsor man connected to active missing person case faces ... - Charleston Post Courier - July 19th, 2023 [July 19th, 2023]
- How bad is a Phoenix heat wave? The perils of burning pavements ... - The Washington Post - July 19th, 2023 [July 19th, 2023]
- Human Insulin Market Demand, In-depth Analysis and Estimated ... - Digital Journal - July 19th, 2023 [July 19th, 2023]
- Film Commentary: How I Learned to Start Worrying and Fear the Bot" - artsfuse.org - July 19th, 2023 [July 19th, 2023]
- Six curators talk about the artists on their radar - ArtsHub - July 19th, 2023 [July 19th, 2023]
- The Biggest X-Men Wins In Marvel Comics Last Five Years - CBR - Comic Book Resources - July 19th, 2023 [July 19th, 2023]
- A mom owed nearly $102000 for her son's stay in a state mental ... - NPR - July 19th, 2023 [July 19th, 2023]
- Federal Ruling Approves Construction of North America's Largest ... - Slashdot - July 19th, 2023 [July 19th, 2023]
- Program To Attract Tech Workers From the US Hits Capacity On ... - Slashdot - July 19th, 2023 [July 19th, 2023]
- Partial convergence of the human vaginal and rectal maternal ... - Nature.com - June 18th, 2023 [June 18th, 2023]
- Tiny device mimics human vision and memory abilities - Science Daily - June 18th, 2023 [June 18th, 2023]
- A meta-analysis of correction effects in science-relevant ... - Nature.com - June 18th, 2023 [June 18th, 2023]
- Mechanistic basis for potent neutralization of Sin Nombre hantavirus ... - Nature.com - June 18th, 2023 [June 18th, 2023]
- Doctors Are Using ChatGPT to Improve How They Talk to Patients - The New York Times - June 18th, 2023 [June 18th, 2023]
- Libya: Briefing and Consultations : What's In Blue - Security Council Report - June 18th, 2023 [June 18th, 2023]
- Water managers tend to focus on climate adaptation, shy away from ... - The Longmont Leader - June 18th, 2023 [June 18th, 2023]
- North America's Weather Turns Weird, Wild, and Extreme. Here's Why - Slashdot - June 18th, 2023 [June 18th, 2023]
- LSD Fact Check: Fake photos implying human with lumpy skin ... - Morung Express - June 18th, 2023 [June 18th, 2023]
- Sir Ben Okri: Being honoured means helping the human race to be ... - msnNOW - June 18th, 2023 [June 18th, 2023]
- Shock and Awe: Life in Iraq Twenty Years after the US-led Invasion - Arab Center Washington DC - June 18th, 2023 [June 18th, 2023]
- Florida man allegedly killed stepdaughters ex in front of victims 4-year-old just hours after he was awarded split custody: Police - Law & Crime - March 31st, 2023 [March 31st, 2023]
- Organ on a chip: The new lab setup scientists are using instead of animals to test new drugs - The Hindu - February 26th, 2023 [February 26th, 2023]
- QCPD arrests UP prof over alleged non-remittance of SSS contributions; orgs call for her release - GMA News Online - February 7th, 2023 [February 7th, 2023]
- Disappointing end to UK space mission as satellites fail to reach orbit - The Guardian - January 10th, 2023 [January 10th, 2023]
- We got space suits at a thrift shop for 20cents & learned theyre real NASA apparel worth $1,000s thanks t... - The US Sun - January 10th, 2023 [January 10th, 2023]
- Boeing: Space Overview - November 25th, 2022 [November 25th, 2022]
- Did Darwin Say It Is 'Not the Strongest of Species That Survives' but the 'Most Adaptable'? - Snopes.com - October 17th, 2022 [October 17th, 2022]
- Descendant of 'Dracula' author to share 'story behind the story' - Bowling Green Daily News - October 17th, 2022 [October 17th, 2022]
- Oct. 13 Letters to the Editor: Our Readers' Opinions - Lewiston Morning Tribune - October 17th, 2022 [October 17th, 2022]
- Royal commission into veteran suicides to commence hearings in Darwin this week - ABC News - October 17th, 2022 [October 17th, 2022]
- GOP secretary of state nominees will appear at event with Lara Logan, who pushes antisemitic conspiracy theories - Media Matters for America - October 17th, 2022 [October 17th, 2022]
- Augmenting the past to appeal to new museum audiences - ArtsHub - October 17th, 2022 [October 17th, 2022]
- Hard-hit citrus industry in Florida will mean higher consumer prices - FreshPlaza.com - October 15th, 2022 [October 15th, 2022]
- Chorley teen with Asperger's selected to represent the UK in judo at Virtus Games in Australia - Lancashire Evening Post - October 15th, 2022 [October 15th, 2022]
- The Datasets Were Looking At This Week - FiveThirtyEight - October 6th, 2022 [October 6th, 2022]
- Before Dark Web, The First Appearance Of Spider-Clone Ben Reilly - Bleeding Cool News - October 2nd, 2022 [October 2nd, 2022]
- The Wrangler Clone Jeep Wants To Ban - SlashGear - October 2nd, 2022 [October 2nd, 2022]
- Range Rover stolen in Birmingham found in Scotland with cloned plates - Birmingham Live - October 2nd, 2022 [October 2nd, 2022]
- The 10 Best Clones in 'Star Wars' Canon, Ranked - We Got This Covered - October 2nd, 2022 [October 2nd, 2022]
- Lori Harvey is Dating 'They Cloned Tyrone' Star John Boyega - TheTealMango - October 2nd, 2022 [October 2nd, 2022]
- John Oliver Warns Us About a Trump Clone With the Army on His Side - Rolling Stone - October 2nd, 2022 [October 2nd, 2022]
- Hold court in house once owned by Clones rugby and tennis star - Independent.ie - October 2nd, 2022 [October 2nd, 2022]
- OnePlus 11R Specs Reveal A OnePlus 10T Clone Almost - Android Headlines - October 2nd, 2022 [October 2nd, 2022]
- What the $70 iPhone 14 Pro Max clone offers - Royals Blue - October 2nd, 2022 [October 2nd, 2022]
- UK Government Bodies Behind Nanotechnology Research Funding - AZoNano - August 30th, 2022 [August 30th, 2022]
- Bar-Ilan University researchers produce nanodiamonds capable of delivering medicinal and cosmetic remedies through the skin - EurekAlert - August 30th, 2022 [August 30th, 2022]
- BYD to Participate in the 2022 Paris Motor Show and reveal Dolphin, Seal, and Yuan Plus for Europe - CarNewsChina - July 31st, 2022 [July 31st, 2022]
- NCIS: Los Angeles Season 14 is not coming to CBS in August 2022 - Web News Observer - July 31st, 2022 [July 31st, 2022]
- The Absolute Best Ways To Keep Bell Peppers Fresh - Tasting Table - July 31st, 2022 [July 31st, 2022]
- Deepika Padukone and Ranveer Singh Set the Runway on Fire; Manish Malhotra calls them Phenomenal - News18 - July 31st, 2022 [July 31st, 2022]
- ITR filing: Having trouble with e-verification, legal heir registration, check these FAQs by Income Tax Dept - Times Now - July 31st, 2022 [July 31st, 2022]
- Moomoo Releases New Data: 84% Of US Adults Regularly Worry About Their Finances; Fewer Than Half Had Money Management Education - PR Newswire - May 20th, 2022 [May 20th, 2022]
- Could Will Smith lose his Oscar? Explaining the Academy's code of conduct - New York Post - March 29th, 2022 [March 29th, 2022]
- Supercharging the future by balancing technology with human intervention - Firstpost - March 29th, 2022 [March 29th, 2022]
- Bring Me The Horizon Have Achieved Their First Ever Billboard 100 Track With 'Maybe' - ROCKSOUND.TV - March 29th, 2022 [March 29th, 2022]
- The internet is crucial - Human Rights Watch - March 29th, 2022 [March 29th, 2022]
- Kirby and the Forgotten Land Review - Niche Gamer - March 29th, 2022 [March 29th, 2022]
- Plastic microparticles discovered in human blood for the first time - National Post - March 29th, 2022 [March 29th, 2022]
- Ukraine: War and the Challenge of Human Rights in the U.S. and Beyond - Scheerpost.com - March 29th, 2022 [March 29th, 2022]
- Teen girls accused of abducting baby told mother they were human trafficking victims - National Post - March 29th, 2022 [March 29th, 2022]
- Amnesty International Report 2021/22: The state of the world's human rights [EN/AR] - World - ReliefWeb - March 29th, 2022 [March 29th, 2022]
- Who Was Leonora Carrington? The Untold Story of the Mystical Surrealist Whose Visions Shaped the 2022 Venice Biennale - artnet News - March 29th, 2022 [March 29th, 2022]
- Time Has Come for Women & Girls in The Post-2020 Global Biodiversity Framework - IDN InDepthNews | Analysis That Matters - March 29th, 2022 [March 29th, 2022]
- Human Centric Lighting Market Top Players, Size, Emerging Trends, Share, Growth, Insights, Industry Analysis, and Forecasts Report 2027 - Digital... - March 29th, 2022 [March 29th, 2022]
- COVID-19 symptoms are reduced by targeted hydration of the nose, larynx and trachea | Scientific Reports - Nature.com - March 29th, 2022 [March 29th, 2022]
- Winner with a human touch: Girmay finds a home from home at Intermarch - Cyclingnews.com - March 29th, 2022 [March 29th, 2022]
- Update on the Democratic Republic of Congo, 29 March 2022 - Democratic Republic of the Congo - ReliefWeb - March 29th, 2022 [March 29th, 2022]
- Israel's 55-year occupation of Palestinian Territory is apartheid UN human rights expert - occupied Palestinian territory - ReliefWeb - March 29th, 2022 [March 29th, 2022]
- Pope evokes specter of nuclear war wiping out humanity - National Post - March 17th, 2022 [March 17th, 2022]
- The Future is Vast: Longtermism's perspective on humanity's past, present, and future - Our World in Data - March 17th, 2022 [March 17th, 2022]
- Human costs mount in the third week of war in Ukraine - Al Jazeera English - March 17th, 2022 [March 17th, 2022]
- 'Human hunter' sentenced to seven months for chasing couple with machete - Calgary Herald - March 17th, 2022 [March 17th, 2022]
- Here's How The Human Brain Reboots Itself After The Deep Sleep of Anesthesia - ScienceAlert - March 17th, 2022 [March 17th, 2022]